NFKB1 and acute lymphoblastic leukemia: Although needing confirmation with primary samples, these reports indicate that NF-κB inhibitors (e.g., proteasomal or IKKβ inhibitors) can induce T-ALL apoptosis and can be of therapeutic value either as stand-alone therapy or as an additional tool to improve standard chemotherapy regimens currently in use.